![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves MSK’s IMPACT Tumor Profiling Assay
FDA Approves MSK’s IMPACT Tumor Profiling Assay
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
November 16, 2017
The FDA authorized Memorial Sloan Kettering Cancer Center’s IMPACT in vitro diagnostic test for tumor profiling, noting the assay can identify a higher number of genetic mutations in cancers than any test previously reviewed by the agency.
The IMPACT assay uses next-generation sequencing to rapidly identify the presence of mutations in 468 unique genes, as well as other molecular changes in the tumor.
The IMPACT test was reviewed through the de novo premarket review pathway.
Upcoming Events
-
21Oct